Interactions between Human Glutamate Carboxypeptidase II and Urea-Based Inhibitors: Structural Characterization

被引:143
作者
Barinka, Cyril [1 ]
Byun, Youngjoo [4 ]
Dusich, Crystal L. [4 ]
Banerjee, Sangeeta R. [4 ]
Chen, Ying [4 ]
Castanares, Mark [2 ]
Kozikowski, Alan P. [3 ]
Mease, Ronnie C. [4 ]
Pomper, Martin G. [2 ,4 ]
Lubkowski, Jacek [1 ]
机构
[1] NCI, Ctr Canc Res, Frederick, MD 21702 USA
[2] Johns Hopkins Med Inst, Dept Pharmacol & Mol Sci, Baltimore, MD 21231 USA
[3] Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA
[4] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21231 USA
关键词
D O I
10.1021/jm800765e
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Urea-based, low molecular weight ligands of glutamate carboxypeptidase II (GCPII) have demonstrated efficacy in various models of neurological disorders and call serve as imaging agents for prostate cancer. To enhance further development of such compounds, we determined X-ray structures Of four complexes between human GCPII and urea-based inhibitors at high resolution. All ligands demonstrate in invariant glutarate moiety within the S1' pocket of the enzyme. The Ureido linkage between P1 and P1' inhibitor sites interacts with the active-site Zn-1(2+) ion and the side chains of Tyr552 and His553. Interactions within the S I pocket are defined primarily by a network of hydrogen bonds between the P1 carboxylate group of the inhibitors and the side chains of Arg534, Arg536, and Asn519. Importantly, we have identified a hydrophobic pocket accessory to the S1 site that call be exploited for structure-based design of novel GCPII inhibitors with increased lipophilicity.
引用
收藏
页码:7737 / 7743
页数:7
相关论文
共 42 条
  • [1] Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II
    Barinka, C
    Rinnová, M
    Sácha, P
    Rojas, C
    Majer, P
    Slusher, BS
    Konvalinka, J
    [J]. JOURNAL OF NEUROCHEMISTRY, 2002, 80 (03) : 477 - 487
  • [2] Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs
    Barinka, Cyril
    Hlouchova, Klara
    Rovenska, Miroslava
    Majer, Pavel
    Dauter, Miroslawa
    Hin, Niyada
    Ko, Yao-Sen
    Tsukamoto, Takashi
    Slusher, Barbara S.
    Konvalinka, Jan
    Lubkowski, Jacek
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2008, 376 (05) : 1438 - 1450
  • [3] Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II
    Barinka, Cyril
    Rovenska, Miroslava
    Mlcochova, Petra
    Hlouchova, Klara
    Plechanovova, Anna
    Majer, Pavel
    Tsukamoto, Takashi
    Slusher, Barbara S.
    Konvalinka, Jan
    Lubkowski, Jacek
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (14) : 3267 - 3273
  • [4] A high-resolution structure of ligand-free human glutamate carboxypeptidase II
    Barinka, Cyril
    Starkova, Jana
    Konvalinka, Jan
    Lubkowski, Jacek
    [J]. ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS, 2007, 63 : 150 - 153
  • [5] Bostwick DG, 1998, CANCER-AM CANCER SOC, V82, P2256, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO
  • [6] 2-S
  • [7] Chang SS, 1999, CLIN CANCER RES, V5, P2674
  • [8] Chen Y., 2007, J NUCL MED, V48
  • [9] The role of excitotoxicity in neurodegenerative disease: Implications for therapy
    Doble, A
    [J]. PHARMACOLOGY & THERAPEUTICS, 1999, 81 (03) : 163 - 221
  • [10] Radiolabeled small-molecule ligands for prostate-specific membrane antigen:: In vivo imaging in experimental models of prostate cancer
    Foss, CA
    Mease, RC
    Fan, H
    Wang, YC
    Ravert, HT
    Dannals, RF
    Olszewski, RT
    Heston, WD
    Kozikowski, AP
    Pomper, MG
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (11) : 4022 - 4028